

CURRICULUM VITAE

Revised: September, 2015

Jeffrey J. Olson, MD

CURRENT TITLES AND AFFILIATIONS:

Academic Appointments

Years	Appointment	Institution
9/2001	Professor of Neurosurgery	Emory University School of Medicine
7/2008	Professor of Hematology and Medical Oncology	Emory University School of Medicine

PREVIOUS ACADEMIC AND PROFESSIONAL APPOINTMENTS:

Years	Appointment	Institution
1989-1990	Assistant Professor of Neurosurgery	George Washington University
1990-1994	Assistant Professor of Neurosurgery	Emory University School of Medicine
9/1994-8/2001	Associate Professor of Neurosurgery	Emory University School of Medicine

PREVIOUS ADMINISTRATIVE APPOINTMENTS:

National

<u>Organization/Committee</u>	<u>Office</u>	<u>Years</u>
Radiation Therapy Oncology Group Neurosurgical Subcommittee	Member	1/1/1993 – 12/31/2001
Eastern Cooperative Oncology Group Brain Committee	Member	1/1/1993 – 12/31/2001
American Association of Neurological Surgeons Membership Benefits Committee	Member	4/1/2000 – 5/3/2004
American Association of Neurological Surgeons Outcomes Committee	Member	10/1/2001 – 9/30/2004
Congress of Neurological Surgeons Executive Committee, Joint Section on Tumors, Guidelines Committee AANS/CNS Joint Section on Tumors	Member	7/1/2001 – 4/15/07

Membership Committee	Chair	10/2009 – 9/2010
American College of Surgeons	Member	11/1/1997 – Present
Commission on Cancer	Member	11/1/1997 - 10/31/2007
Committee on Approvals	Member	
Post-Graduate Education Subcommittee	Member	
Melanoma Disease Site Committee	Member	
American Board of Neurological Surgery	Guest Examiner	5/18-21/2010
American College of Radiology	Member	5/2010-5/2013
Panel on Musculoskeletal Imaging		

State and Regional

<u>Organization</u>	<u>Title</u>	<u>Years</u>
Georgia Neurosurgical Society	Program Chairman	1992-1993
Georgia Neurosurgical Society	President	2010-2011

Institutional

Emory University School of Medicine Committee Memberships

<u>Committee</u>	<u>Title</u>	<u>Years</u>
Winship Cancer Center Safety Committee	Chairman	1/1/1993 – 12/31/1995
Clinical Executive Committee, Winship Cancer Center	Member	3/1/1994 – 3/31/2000
Clinical Research Review Committee, Winship Cancer Center	Member	1/1/1994 – 12/1/1998
PET Center Committee	Member	1/1/1991 – 12/31/1999
Faculty Committee on Appointments and Promotions	Member and Ad Hoc Committee Chair	10/1/1996 – 9/30/2005

Emory University Hospital Committee Memberships

<u>Committee</u>	<u>Title</u>	<u>Years</u>
Medical Quality Improvement Committee	Member	6/1/1991 to 12/1/1995
Medical Records Committee	Member	1/1/1993 – 12/31/1995
Cancer Committee, Emory University Hospital	Member	10/1/2000 – 9/30/2003

Emory Clinic Committee Memberships

<u>Committee</u>	<u>Title</u>	<u>Years</u>
Risk Management Committee, Emory Clinic	Member	7/1/1996 – 12/31/1998
Safety Committee, Emory Clinic, Member	Member	1/1/1997 – 12/31/1998

LICENSURES/BOARDS:

Licensure

<u>State</u>	<u>Date Licensed</u>	<u>Number</u>
State of Iowa	8/25/83	23848 (Inactive)
State of Illinois	7/31/84	036-068805 (Inactive)
State of Maryland	8/5/87	D35535 (Inactive)
District of Columbia	8/9/89	18025 (Inactive)
State of Georgia	8/13/90	33418

Board Certification:

<u>Board</u>	<u>Date Certified</u>	<u>Number</u>
National Board of Medical Examiners	7/1/1982	251271

SPECIALTY BOARDS:

<u>Board</u>	<u>Date Certified</u>	<u>Number</u>
American Board of Neurological Surgery	9/13/1989	8901

EDUCATION:

August 1973 - May 1977	B.A. Concordia College Moorhead, Minnesota
September 1977 - June 1981	M.D. University of Minnesota Minneapolis, Minnesota

POSTGRADUATE EDUCATION:

<u>Position</u>	<u>Location</u>	<u>Supervisor</u>	<u>Dates</u>
Surgical Internship	University of Iowa Hospitals Iowa City, IA	John C. VanGilder, M.D.	7/1/1981 – 6/30/1982
Neurosurgery	University of Iowa Hospitals	John C. VanGilder, M.D.	7/1/1982 – 6/30/1987
Residency	Iowa City, IA		
Senior Staff Fellow Surgical Neurology	National Institutes of Health National Institute of Neuro- logical Disorders and Stroke Bethesda, MD	Edward Oldfield, M.D.	7/1/1987 – 6/30/1990

MILITARY OR GOVERNMENT SERVICE:

None

CURRENT COMMITTEE MEMBERSHIPS:**National and International:**

<u>Organization/Committee</u>	<u>Office</u>	<u>Years</u>
ABTC CNS Consortium Neurosurgical Committee	Member	5/15/1996 – 12/31/2014
AANS/CNS Joint Section on Tumors	Member	9/10/10 – Present
Joint Guidelines Committee	Member	10/8/12 – Present
Progressive Glioblastoma Guidelines Task Force	Chairman	4/23/11 - 6/1/2014
Low Grade Glioma Guidelines Task Force	Chairman	12/16/12 – Present
Vestibular Schwannoma Guidelines Task Force	Chairman	10/25/14 – Present
Congress of Neurological Surgeons Joint Guidelines Committee	Member	4/1/2014 – Present

Institutional**Emory University School of Medicine**

<u>Committee</u>	<u>Office</u>	<u>Years</u>
Neuro-oncology Working Group, Winship Cancer Institute	Chairman	12/1/1995 – present

Emory Clinic

Neurosurgery Departmental Committee Memberships

<u>Committee</u>	<u>Office</u>	<u>Years</u>
Credentialing Committee	Member	11/1/1991 – present
Research Committee	Member	1/1/1992 – present
Operations Committee	Member	5/1/2003 – present

CONSULTANTSHIPS:

<u>Organization/Committee</u>	<u>Office</u>	<u>Years</u>
Department of Energy Office of Health & Environmental Research Technical Advisory Committee. Boron Neutron Capture Therapy University Consortium	Member	5/1/1993 – 12/1/1995
Department of Energy Nuclear Medicine Program Peer Review Panel	Member	August 11-13, 1992

Proxima Therapeutics, Inc.	Medical Advisory Board	1/1/1995 – 4/1/2005
Cytodome, Inc.	Scientific Advisory Board	9/29/2005 – 9/30/2010
Georgia Department of Community Health/ Division of Health Planning Stereotactic Radiosurgery Services Technical Advisor Committee	Member	12/13/06 – 9/27/2007
Monteris Medical	Data Safety Monitoring Board	8/7/08 – 8/6/11
American Cancer Society	Editorial Consultant	10/1/07 Present
FDA Orphan Products Development Program	Grant Review Panel Member	5/21/2013

STUDY SECTION MEMBERSHIPS:

Developmental Therapeutics Study Section National Institutes of Health Advisor Committee	Ad Hoc Member	9/27-28/2007
---	---------------	--------------

EDITORIAL BOARDS:

<u>Publication</u>	<u>Year</u>
Contemporary Neurosurgery	4/1992 – 12/1996
Clinical Neurosurgery	4/1993 – 12/1995

MANUSCRIPT REVIEWER:

<u>Publication</u>	<u>Year</u>
Neurosurgery	1989 – 1993, 2010- present
Neuroscience Letters	1993 – present
Cancer	1990 – present
Journal of Neuro-oncology	2007 - present

HONORS AND AWARDS:

<u>Name</u>	<u>Year</u>
Magna cum laude, Concordia College, Moorhead, Minnesota	1977
Best Scientific Paper, Resident Research Day University of Iowa Hospitals and Clinics	1985
First Place Basic Neuroscience Poster Session "Methylprednisolone reduces the bulk flow of water across an in vitro blood brain barrier" American Association of Neurological Surgeons	1987

Young Clinician Investigator Award 1991
American Association of Neurological Surgeons

SOCIETY MEMBERSHIPS:

<u>Society</u>	<u>Years</u>
Congress of Neurological Surgeons	March, 1988 – present
American Association of Neurological Surgeons	October, 1990 – present
Medical Association of Georgia	January, 1991 – present
Georgia Neurosurgical Society	May, 1991 – present
Society of Surgical Oncology	January, 1993 – October, 2009
American College of Surgeons	October, 1997– present

ORGANIZATION OF LOCAL, NATIONAL AND INTERNATIONAL CONFERENCES:

<u>Course</u>	<u>Position</u>	<u>Date</u>
Practical Course Committee Lasers in Neurosurgery Session Congress of Neurological Surgeons, Atlanta, Georgia	Session Chair	September, 1989
13 th International Conference on Brain Tumor Research & Therapy Lake Toya, Hokkaido, Japan, October 3-6, 1999.	Scientific Advisory Board	October, 1999
Neurosurgery and Neurology Update for the Primary Care Physician, Emory University School of Medicine	Course Chairman	8/1993–12/1997
Neuro-oncology Update Emory University	Course Co-Chairman	5/04 - 10/05

RESEARCH FOCUS:

Investigational therapies of brain tumors have been the primary thrust of my research. This includes analysis of new agents or modification of established regimens using brain tumor models *in vitro* and *in vivo*. A strong emphasis on clinical investigations has been maintained to provide for accomplishment of translational work.

GRANT SUPPORT:

Active Support

Federal

1. Project Title:	R01 CA121320-01: MR Investigation of IDH Mutation and It's Marker 2-HG in Brain Tumor Patients
Role in Project:	Co- Investigator (3% effort, PI: H. Mao)
Funding Agency:	National Cancer Institute
Term:	4/15/13 – 3/31/18
Amount:	\$1,783,411 Total over term of grant

2. Project Title: Quantitative MRSI to predict early response to SAHA therapy in new GBM management
 Role in Project: Effort (Multiple PIs: Shu/Olson/Hu/Shim (contact))
 Funding Agency: NIH/NCI U01 CA172027
 Term: August 6, 2013 – July 31, 2018
 Amount: \$3,958,750 Total over term of grant

3. Project Title: R21 CA186169 Combining high resolution MRSI with 5-ALA to improve complete resection in GBM surgery.
 Role in Project: Co-Investigator, 3% Effort (Multiple PIs: Holder/Hadjipanayis/Shim (contact))
 Funding Agency: NIH/NCI
 Dates: April 2014 – March 2016
 Amount: Total Costs: \$792,125 (direct + indirect)

4. Project Title: 1U10CA180864-01 Winship Cancer Institute National Clinical Trials Network Lead Academic Participating Site
 Role in Project: Co-Investigator, 3% Effort (Multiple PIs: Ramalingam/Beitler/Staley)
 Funding Agency: NIH/NCI
 Dates: 3/01/2014 – 2/28/2019
 Amount: Total Costs: \$348,045 (annual direct)

Contracts

None currently

Previous Support

Federal

1. Project Title: Boron Neutron Capture Therapy of Glioblastoma Multiforme at the Brookhaven Medical Research Reactor
 Role in Project: Principal Investigator
 Funding Agency: Department of Energy
 Term: 4/1/95 - 7/31/96
 Amount: Total \$26,000 (\$6500/patient)

2. Project Title: PEG-modified Liposomes for Boron Neutron Capture Therapy
 Role in Project: Co- Investigator (PI: D. Robert Lu, Ph.D., Univ of GA)

- Funding Agency: National Institutes of Health: National Cancer Institute
Term: 7/1/96 - 6/30/99
Amount: \$73,670 (Direct Costs)
3. Project Title: Consortium Therapeutic Studies of Primary Central Nervous System Malignancies in Adults
Role in Project: Co-Principal Investigator
Funding Agency: National Cancer Institute
Term: 1/1/98 - 7/31/00
Amount: \$150,000 direct costs
4. Project Title: Carboranyl Nucleosides and Oligonucleotides for Neutron Capture Therapy
Role in Project: Co-Investigator [PI: Raymond Schinazi, Ph.D]
Funding Agency: Department of Energy
Term: 7/1/00 - 6/30/03
Amount: \$45,540 in annual direct costs for each of three years
5. Project Title: Development of Novel Fluorinated Amino Acids
Role in Project: Co-Investigator
Funding Agency: National Institutes of Health (NCI)
Term: 10/01/02 – 09/30/04
Amount: \$250,000 in direct costs for two years
6. Project Title: R21CA141836: Using Proton MRS to Predict Response of SAHA treatment in Glioblastomas
Role in Project: Principal Investigator (5% effort)
Funding Agency: National Cancer Institute
Term: 10/1/10 - 9/30/12
Amount: \$326,174/Year 1
7. Project Title: R01 CA116174: Southeast Region Case Control Study of Adult Glioma
Role in Project: Co-investigator (0.36% effort)
Funding Agency: National Cancer Institute
Term: 6/1/07-5/31/12
Amount: \$ 74,610 (Emory Subcontract)
8. Project Title: UO1CA137433-01: Adult Brain Tumor Consortium
Role in Project: Emory Principal Investigator (1% effort, PI: S. Grossman)
Funding Agency: National Cancer Institute
Term: 1/1/09 - 7/31/15
Amount: \$3000/patient enrolled (Emory Subcontract)
9. Project Title: RO1CA169937-01: Leucine Type Amino Acid Transport in Gliomas

Role in Project: Co- Investigator (5% effort, PI: M. Goodman)
Funding Agency: National Cancer Institute
Term: 7/1/07 – 6/30/15
Amount: \$2,830,537 Direct over term of grant

Private Foundation

1. Project Title: The Investigation of Basic Fibroblastic Growth Factor Release from Extracellular Matrix by Malignant Brain Tumors
Role in Project: Principal Investigator
Funding Agency: Young Clinician Investigator Award
American Association of Neurological Surgeons
Term: 5/91 - 4/92
Amount: \$40,000
2. Project Title: Hormonal manipulation of Meningiomas
Role in Project: Principal Investigator
Funding Agency: Winship Cancer Center, American Cancer Society
Term: 11/1/92 - IO/31/93
Amount: \$8,532.
3. Project Title: Cerebral Endothelial Responses to Fluid Shear Stress: Possible Role in the Pathogenesis of Intracranial Aneurysms.
Role in Project: Collaborating Investigator
Funding Agency: American Heart Association
Term: 7/1/93 - 6/30/95
Amount: \$30,000
2. Project Title: The Role of Cytokines in Brain Tumor Therapy
Role in Project: Principal Investigator
Funding Agency: MBNA America
Term: 7/1/96 - 6/30/97
Amount: \$40,000

Contracts

1. Project Title: A Double-Blind, Placebo controlled Study of BCNU Delivered from Biodel, a Biodegradable, Surgically Implanted Polymer for the Treatment of Recurrent, Malignant Glioma
Role in Project: Principal Investigator

- Funding Agency: Nova Pharmaceutical Corporation
 Term: 7/90 - 1/92, 11/93 - 11/94
 Amount: \$24,263
2. Project Title: Phase III Trial of Crisnatol in Consolidative Therapy of Glioblastoma Multiforme
 Role in Project: Principal Investigator
 Funding Agency: ILEX Oncology, Inc.
 Term: 11/12/94 - 11/11/96
 Amount: \$4947/patient
3. Project Title: Correlation of Interferon alpha gene deletion with Response to Interferon alpha-2a Treatment in Recurrent Primary Malignant Gliomas
 Role in Project: Principal Investigator
 Funding Agency: Hoffman-LaRoche
 Term: 12/5/94 - 12/4/95
 Amount: Direct \$16,667. Indirect \$3333.
4. Project Title: A Randomized, Open Label, Phase II Study of Temozolomide and Reference Agent in the Treatment of Patients with Glioblastoma Multiforme at First Relapse
 Role in Project: Principal Investigator
 Funding Agency: Schering-Plough, Inc.
 Term: 1/1/95 - 2/16/99
 Amount: \$165,820
5. Project Title: Temozolomide in the Therapy of Patients with Anaplastic Astrocytoma at First Relapse
 Role in Project: Principal Investigator
 Funding Agency: Schering-Plough, Inc.
 Term: 3/1/95 - 2/16/99
 Amount: \$48,413
6. Project Title: Investigation of the Safety and Efficacy of Frameless Stereotaxy in Cranial Surgery
 Role in Project: Principal Investigator
 Funding Agency: Phillips Medical, Inc.
 Term: 4/1/95 - 8/31/95
 Amount: \$38,577 (Direct Costs)
7. Project Title: A Multi-Center Open-Label, Single Arm, Phase II Study of RMP-7 and Carboplatin, Administered Intra-arterially for the Treatment of Malignant Glioma
 Role in Project: Principal Investigator
 Funding Agency: Alkermes
 Term: 4/1/96 - 3/31/97

- Amount: \$57,277
8. Project Title: Prospective, Open-Label, Parallel-Group, Randomized, Multi-Center Trial Comparing the Efficacy of Surgery, Radiation, and Injection of Murine Cells Producing Herpes Simplex Thymidine Kinase Vector Followed by Intravenous Ganciclovir Against the Efficacy of Surgery and Radiation in the Treatment of Newly Diagnosed, Previously Untreated Glioblastoma
- Role in Project: Principal Investigator
Funding Agency: Genetic Therapy, Inc.
Term: 6/1/96 - 5/31/00
Amount: \$97,435
9. Project Title: Analysis of a Cerebral Balloon Catheter System
- Role in Project: Principal Investigator
Funding Agency: Oncocath, Inc.
Term: 7/1/97 - 12/31/98
Amount: \$97,108 (Direct and Indirect)
10. Project Title: Temozolomide in Patients with Newly Diagnosed Supratentorial Malignant Glioma
- Role in Project: Principal Investigator
Funding Agency: Schering-Plough Corporation
Term: 11/12/97 - 11/11/99
Amount: \$168,813
11. Project Title: Transduction Efficiency, Toxicity and Efficacy of Wild Type p53 Gene Delivery Utilizing an Adenoviral Vector in an Intracranial Tumor Model
- Role in Project: Principal Investigator
Funding Agency: Schering-Plough Corporation
Term: 1/1/98 - 12/31/98
Amount: \$22,226 direct costs
12. Project Title: Safety and Efficacy of Polyetherurethane as a Dural Substitute
- Role in Project: Principal Investigator
Funding Agency: Aesculap, Inc.
Term: 8/1/98 - 12/31/99
Amount: \$10,000 direct costs
13. Project Title: The Efficacy of Ventricular Catheters Impregnated with Minocycline and Rifampin versus Standard Ventricular Catheters in the Reduction of Catheter Infection
- Role in Project: Principal Investigator
Funding Agency: Cook, Inc.

- Term: 8/1/99 - 7/31/00
Amount: \$4800
14. Project Title: The Safety and Efficacy of Proxima GliaSite RTS
Role in Project: Principal Investigator
Funding Agency: Proxima Therapeutics, Inc.
Term: 10/14/99 - 7/31/00
Amount: \$33,160 total costs
15. Project Title: Phase II Study Utilizing the GliaSite RTS for the Treatment of a Resected Solitary Brain Metastasis
Role in Project: Principal Investigator
Funding Agency: Proxima Therapeutics, Inc.
Term: 11/9/01 - 11/9/02
Amount: \$1400 direct costs/patient
16. Project Title: Clinical Study to Determine the Patient Benefits and Safety of Depocyt for the Treatment of Neoplastic Meningitis
Role in Project: Principal Investigator
Funding Agency: Skyepharma, Inc.
Term: 12/1/01 – 05/31/03
Amount: \$13,800/patient
17. Project Title: Dose-Escalation, Safety and Tolerability Study of NBI-3001 Administered by Continuous Intratumoral Infusion
Role in Project: Principal Investigator
Funding Agency: Neurocrine Bioscience, Inc.
Term: 9/1/01 - 6/15/02
Amount: \$24, 948 direct costs (\$6,237) per subject
18. Project Title: Safety and Performance of a Multi-modality Fluid Delivery Device
Role in Project: Principal Investigator
Funding Agency: Proxima Therapeutics, Inc.
Term: 6/13/01 – 12/31/03
Amount: \$68,151 direct costs (\$25,216 indirect costs)
19. Project Title: Imaging Analysis of Amino Acid Metabolism in Intracranial Tumors Using PET and (18F)FACBC
Role in Project: Principal Investigator
Funding Agency: Nihon Medi-Physics Co., Ltd.
Term: 10/1/02 – 12/31/03
Amount: \$233,365

20. Project Title: Clinical Study of the Medtronic Durepair Dura Regeneration Matrix
 Role in Project: Principal Investigator
 Funding Agency: Medtronic, Inc
 Term: 2/9/04 – 2/9/07
 Amount: \$68,675
21. Project Title: A Phase I/II Dose Escalation Study to Assess the Toxicity and Efficacy of Intratumoral DepoCyt in the Normal Rat and in 9L-Gliosarcoma in the Fisher 344 Rat
 Role in Project: Principal Investigator
 Funding Agency: Enzon, Inc
 Term: 6/1/06 – 6/31/08
 Amount: \$33,500
22. Project Title: Phase II open label multiple dose study of intracavitary administration of 131-I TM-601 in adults with recurrent high grade glioma.
 Role in Project: Principal Investigator
 Funding Agency: Transmolecular, Inc
 Term: 4/1/07 – 3/31/08
 Amount: \$117, 991
23. Project Title: A Phase II Study of Temozolomide and O6-Benzylguanine (O6-BG) in Patients with Temozolomide-Resistant Anaplastic Glioma
 Role in Project: Principal Investigator
 Funding Agency: AOI Pharmaceuticals, Inc
 Term: 5/1/07 – 4/30/09
 Amount: \$97,500
24. Project Title: Dose Finding Phase 1 Study of the Treatment of Recurrent/Relapsed Glioblastoma Multiforme with MPC-6827 in Combination with Oxaliplatin
 Role in Project: Emory Principal Investigator
 Funding Agency: Myriad Pharmaceuticals, Inc
 Term: 5/1/07 – 10/30/09
 Amount: \$141,013.85
25. Project Title: Assessment of Systemically Administered Torisel Delivery to Brain Tumors by Intratumoral Microdialysis
 Role in Project: Principal Investigator
 Funding Agency: Wyeth, Inc
 Term: 4/1/09 – 3/31/11

- Amount: \$182,802
26. Project Title: An Exploratory Phase 2 Study Evaluating the Efficacy and Safety of Fibrin Sealant, Vapor Heated, Solvent/Detergent treated (FS VH S/D) 500 s-apr for the Sealing of Dura Defect Sutures in Posterior Fossa Surgery
- Role in Project: Principal Investigator
 Funding Agency: Baxter Healthcare Corporation
 Term: 7/2/07 – 8/31/10
 Amount: \$5692.50/patient at an estimated 9 patients/year
27. Project Title: Glioblastoma Stem Cell Resistance to Proteasome Inhibition: Assessment of Mechanisms
- Role in Project: Principal Investigator (1% effort)
 Funding Agency: Southeastern Brain Tumor Foundation
 Term: 1/1/10 – 12/31/10
 Amount: \$50,000 Direct over term of grant

Other

1. Project Title: Release of Basic Fibroblastic Growth Factor from Extracellular Matrix by Malignant Brain Tumors
- Role in Project: Principal Investigator
 Funding Agency: Winship Cancer Center Seed Grant
 Term: 11/90 - 10/91
 Amount: \$8,000
2. Project Title: Cerebral Endothelial Cell Response to Fluid Imposed Shear Stress: A Putative Role in the Pathogenesis of Intracranial Aneurysms and Intracerebral Hypertensive Angiopathy
- Role in Project: Co-investigator
 Funding Agency: Emory/Georgia Tech Biomedical Technology Research Center
 Term: 6/91 - 5/92, Renewable for one additional year.
 Amount: Total grant \$28,000
 \$10,000 for Jeffrey J. Olson (Emory)
3. Project Title: Analysis of PS-341 Distribution and Efficacy in a Rodent Brain Tumor Model
- Role in Project: Principal Investigator
 Funding Agency: University Research Committee, Emory University
 Term: 6/1/00 - 5/31/01
 Amount: \$21,000 direct costs

4. Project Title: Glioblastoma Stem Cell Resistance to Proteasome Inhibition: Assessment of Mechanisms
- Role in Project: Principal Investigator
- Funding Agency: Southeastern Brain Tumor Foundation
- Term: 1/1/10 - 12/31/10
- Amount: \$50,000 direct costs

CLINICAL SERVICE CONTRIBUTIONS:

Adult Brain Tumor Clinic

The Adult Brain Tumor Clinic was established in 1992. This comprises an arrangement for the simultaneous presence of neurosurgery, radiation oncology and neuro-oncology at the same physical site so as to abet brain tumor patient management. It includes a one hour case discussion conference during the middle of the clinic. This conference includes neuroradiology and neuropathology representatives and therefore allows complete consideration to be given to challenging cases. This served as the first adult multidisciplinary clinic at Emory and has met continuously since its inception.

Clinical Research

1. Emory University Principal Investigator on brain tumor protocols for the Brain Tumor Study Group, Eastern Cooperative Oncology Group and Radiation Therapy Oncology Group through 1995.
2. Emory University Principal Investigator on brain tumor protocols for the National Cancer Institute sponsored Adult Brain Tumor Consortium (ABTC, formerly New Approaches to Brain Tumor Therapy Consortium) 1995-2013.

<u>Title</u>	<u>Phase</u>	<u>Tumor Type</u>	<u>Sponsoring Organization</u>
A Phase I Open Label Safety Study to Evaluate the Pharmacokinetic Profile and Tolerance of Mibefradil Dose Finding in Subjects with Recurrent High-Grade Glioma Undergoing Standard, Repeated Temozolomide Treatment	1	High Grade Glioma	ABTC/NCI

3. Principal Investigator insitutional brain tumor protocols. Currently active:

<u>Title</u>	<u>Phase</u>	<u>Tumor Type</u>	<u>Sponsoring Organization</u>
Phase I Trial of Temozolomide, Bevacizumab Plus Bortezomib for Patients with Recurrent Glioblastoma Multiforme	1	Glioblastoma	Merck, Roche, Millenium

FORMAL TEACHING:

Medical Student Teaching

<u>Course</u>	<u>Years</u>
Problem Based Learning Course: Second Year Medical Students Emory University School of Medicine	2000 - 2001

Graduate Program

<u>Course</u>	<u>Years</u>
ISB524: Cancer Biology. Gene Therapy - Background and Applications to Brain Tumors Emory University School of Medicine	1997- 1998

Cancer Center Liaisons

Central Nervous System Tumors Georgia Center for Cancer Statistics	1994
---	------

SUPERVISORY TEACHING:

Training Programs

<u>Course</u>	<u>Years</u>
Neurosurgery Residency Naval Hospital, Bethesda	1987 – 1990
Neurosurgery Residency George Washington University	1989 – 1990
Neurosurgery Residency Emory University	1990 – present
Neurosurgical Oncology Fellowship, Director Emory University	2009 – present

LECTURESHIPS, SEMINAR INVITATION, AND VISITING PROFESSORSHIPS:

Invited Seminar Presentations

<u>Presentation</u>	<u>Seminar</u>	<u>Date</u>
Laboratory Evidence for the Hormonal Dependency of Meningiomas	Terra Symposia III: Progesterone Antagonists	May 27, 1992
Potential Limitations in the Use of Epidermal Growth Factor Receptor as a Therapeutic	Brain Tumor Working Group of the Eastern Cooperative	April 9, 1995

Target in Brain Tumors.	Oncology Group	
Surgical Management of Skull Base Infections	Skull Base Neurosurgical Techniques: An Update and Hands-On Course The Georgia Neurosurgical Society	May 23, 1997
Innovative Therapy for Brain Tumors	Annual George Tindall Lecture Series	March 15, 1996
Innovative Therapy for Brain Tumors	Southern Neurosurgical Society	March 29, 1996
From Benchtop to Bedside. Translational Research in Neuro-oncology	Annual George Tindall Lecture Series	April 3, 1998.
Suramin: Laboratory and Clinical Studies of the Inhibition of Angiogenesis in Glioma Growth	Angiogenesis and Brain Tumor Therapy.	May 16, 1998
Detection and Management of Pseudo-Progression in Glioblastoma	Debates and Didactics in Hematology and Oncology Emory WCI, Sea Island	July 25, 2013
Early vs. Delayed Use of Bevacizumab For High Grade Gliomas	Debates and Didactics in Hematology and Oncology Emory WCI, Sea Island	July 27, 2013

Visiting Professorship

<u>Location</u>	<u>Presentation</u>	<u>Date</u>
Kobe University Kobe, Japan	Aggressive Management of Malignant Brain Tumors	November 17, 1992
Johns Hopkins University Baltimore, MD	PET with FACBC Versus FDG for Analysis of Metastatic and Primary Brain Tumors	September 18, 2003
George Washington University Washington, DC	Hypoxia and Its Role in Brain Tumor Therapy	May 3, 2006

INVITATIONS TO NATIONAL AND INTERNATIONAL CONFERENCES

(Last 5 Years)

<u>Presentation</u>	<u>Conference</u>	<u>Date</u>
Ongoing Clinical Studies: NABTT 2002	European Association of Neuro-Oncology	September 10,

The Proxima Spectrum CED/Brachytherapy Device	ACOSOG CNS Organ Site Committee	March 27, 2003	
Guidelines for the Therapy of Malignant Tumors	Congress of Neurological Surgeons	October 5, 2005	
Contemporary Surgical Approaches and Complications to Lateral Skull Base Tumors	American Association of Neurological Surgeons	April 18, 2007	
Brain Tumor Update 2007 Course Director	Congress of Neurological Surgeons, San Diego	September	16,
Biology of Gliomas 2007	Congress of Neurological Surgeons, Dan Diego	September	16,
Surgical Approaches to the Lateral Skull Base [Course Director]	American Association of Neurological Surgeons	2008-2015	
Emerging Therapies in Metastatic Brain Tumors	Congress of Neurological Surgeons	October, 2009	
Implementing and Utilizing the New AANS/CNS Metastatic Brain Tumor Clinical Practice Guidelines in Everyday Practice"	Congress of Neurological Surgeons	October, 2010; September 2011	
Magnetic Resonance Spectroscopic Imaging Measurement of Early Response To Vorinostat Treatment in Recurrent Glioblastoma	Congress of Neurological Surgeons	October, 2012	
Open Skull Base Surgery: When is the Traditional Approach Necessary?	Congress of Neurological Surgeons	October, 2012	

COMMUNITY SERVICE:

1. Celebration of Living. Speaker on Brain Tumors. Emory University and Winship Cancer Center. 1992-2000, 2002, 2004
2. Moderator, Town Hall Meeting, American Brain Tumor Association. Atlanta, GA. February 1, 1998.

3. Member, Medical Advisory Board. Southeastern Brain Tumor Foundation. August 1, 1998 – present.
4. Moderator and Presenter of the Sharing Hope Program. American Brain Tumor Association. Atlanta, GA. February 29 –March 1, 2008.

BIBLIOGRAPHY:

Published and Accepted Research Articles

1. Hitchon PW, Haque A, Olson JJ, Jacobs SK, Olson SP: Sarcoidosis presenting as an intramedullary spinal cord mass. *Neurosurgery* 15: 86-90, 1984.
2. Olson JJ, Menezes AH, Godersky JC, Hart MN, Lobosky JM: Primary intracranial rhabdomyosarcoma. *Neurosurgery* 17: 25-34, 1985.
3. Olson JJ, Beck DW, Schlechte J, Loh PM: Hormonal manipulation of meningiomas in vitro. *Journal of Neurosurgery* 65: 99-107, 1986.
4. Beck DW, Olson JJ, Urig E: Percutaneous retrogassarian glycerol rhizotomy for the treatment of trigeminal neuralgia. *Journal of Neurosurgery* 65: 28-31, 1986.
5. Beck DW, Olson JJ, Linhardt RJ: Effect of heparin, heparin fragments, and corticosteroids on cerebral endothelial cell growth in vitro and in vivo. *Journal of Neuropathology and Experimental Neurology* 45: 503-512, 1986.
6. Beck DW, Roberts RL, Olson JJ: Glial cells influence membrane associated enzyme activity at the blood-brain barrier. *Brain Research* 381: 131-137, 1986.
7. Olson JJ, Beck DW, Schlechte JA, Loh PM: Effect of the antiprogestone RU38486 on meningioma implanted in nude mice. *Journal of Neurosurgery* 66: 584-587, 1987.
8. Olson JJ, Beck DW, Menezes AH: Comparative evaluation of intracranial epidermoid tumors with computerized tomography and magnetic resonance imaging. *Neurosurgery* 21(3): 357-360, 1987.
9. Olson JJ, Beck DW, Warner DS, Coester H: The role of new vessels and macrophages in the resolution of edema following the cortical freeze lesion in the mouse. *Journal of Neuropathology and Experimental Neurology* 46: 682-694, 1987.
10. Olson JJ, Beck DW, Warner DS: Effect of acute angiographic contrast medium administration on cortical specific gravity after middle cerebral artery occlusion in rats. *Stroke* 18: 924-927, 1987.
11. Olson JJ, Poor MM, Jr., Beck DW: Methylprednisolone reduces bulk flow of water across an in vitro blood-brain barrier. *Brain Research* 439 (1,2): 259-265, 1988.
12. Olson JJ, Beck DW, MacIndoe JW, Loh PM: Androgen receptors in meningiomas. *Cancer* 61: 952-955, 1988.

13. Olson JJ, Loftus CM, Hitchon PW: Metastatic pheochromocytoma of the cervical spine. *Spine* 14: 349-351, 1989.
14. Oldfield EH, Friedman R, Kinsella T, Moquin R, Olson JJ, Orr K, DeLuca AM: Pentobarbital and lidocaine reduce brain injury by ionizing radiation. *Journal of Neurosurgery* 72: 737-744, 1990 .
15. Olson JJ, Friedman R, Orr K, Delaney T, Oldfield EH: Cerebral radioprotection by pentobarbital: Dose-response characteristics and association with GABA agonist activity. *Journal of Neurosurgery* 72: 749-758, 1990.
16. Olson JJ, Friedman R, Orr K, Delaney T, Oldfield EH: Enhancement of the efficacy of x-irradiation by pentobarbital in a rodent tumor model. *Journal of Neurosurgery* 72: 745-748, 1990.
17. Olson JJ, Shelley C, Orr K, Delaney T, Oldfield EH: The cerebral radioprotective effect of alternative barbiturates to pentobarbital. *Neurosurgery* 30(5): 720-723, 1992.
18. Gansler T, Vaghmar N, Olson JJ, Graham SD: Suramin inhibits growth factor binding and proliferation by urothelial carcinoma cell cultures. *Journal of Urology* 148: 910 - 914, 1992.
19. Olson JJ, Reisner A, Klemm JM, Bakay RAE: Basic fibroblastic growth factor as a potential meningeal angiogenic factor. *Skull Base Surgery* 3:117-122, 1993.
20. Olson JJ, Polk DM, Reisner A: The Efficacy and Distribution of Suramin in the Treatment of the 9L Gliosarcoma In Vivo. *Neurosurgery*: 34: 297 - 308, 1994
21. Ekstrand AJ, Largo N, Hamid ML, Olson JJ, Collins VP, James CD: Functional characterization of an EGF receptor with a truncated extracellular domain. *Oncogene* 9: 2313-2320, 1994.
22. Olson JJ: Laboratory Evidence for the Hormonal Dependency of Meningiomas. *Human Reproduction*. 9 (Suppl. 1): 195-201, 1994.
23. Barnett DW, Olson JJ, Thomas W, Hunter SB: Low-grade astrocytomas of the pineal region. *Surgical Neurology* 43: 70-76 1994.
24. Hunter SB, Abbott K, Varma VA, Olson JJ, Barnett DW, James CD: Epidermal Growth Factor Receptor and MDM2 Gene Amplification in Human Gliomas. Detection by Differential PCR in DNAs Extracted from Archival Specimens. *J Neuropathol Exp Neurol* 54: 57-64, 1995.
25. Olson JJ, James CD, Krisht A, Barnett D, Hunter S: Analysis of Epidermal Growth Factor Receptor Gene Amplification and Alteration in Stereotactic Biopsies of Brain Tumors. *Neurosurgery* 36: 740-748, 1995.
26. Reisner A, Olson JJ, Yang J, Assietti R, Klemm JM, Girard PR: Isolation and Culture of Bovine Intracranial Arterial Endothelial Cells. *Neurosurgery* 36: 806-813, 1995.
27. Blevins LS, Hunter SB, Olson JJ, Gussack G: Metastatic follicular thyroid carcinoma masquerading as a chordoma. *Thyroid* 5: 217-221, 1995

28. He J, Olson JJ, James CD: Lack of expression of p16^{ink4} or pRb, or amplification associated with overexpression of CDK4 is observed in distinct subsets of malignant glial tumors and cell lines. *Cancer Research* 21: 4833-4836, 1995.
29. Mehta SC, Olson JJ, Lu R: Brain tissue reaction following intracerebral injection of free or liposomally encapsulated BSH. *Drug Delivery* 2: 175-180, 1995.
30. Zunkeler B, Carson RE, Olson JJ, Blasberg RG, Girton M, Bacher J, Herscovitch P, Oldfield EH: Hyperosmolar blood-brain barrier disruption in primates: An in vivo study using positron emission tomography and rubidium. *J Neurosurg* 84: 494-502, 1996.
31. Assietti R, Olson JJ: Intra-arterial cisplatin in malignant brain tumors: Incidence and severity of otic toxicity and efficacy of treatment. *Journal of Neuro-oncology* 27: 251-258, 1996.
32. He J, Olson JJ, Serbanescu A, Yang J, Offerman MK, James CD: Transfection of IFN- α in Human Glioblastoma Cells Abrogates Tumorigenicity in Association with Induction of PKR and OAS Expression. *J Neurosurg* 85: 1085-1091, 1996.
33. Zunkeler B, Carson RE, Olson JJ, Blasberg RG, DeVroom H, Lutz RJ, Saris SS, Wright DC, Kammerer W, Patronas N, Dedrick RL, Herscovitch P, Oldfield EH: Quantification and Pharmacokinetics of Blood-Brain Barrier Disruption in Humans. *Journal of Neurosurgery* 85: 1056-1066, 1996.
34. Olson JJ, Shepherd S, Bakay RAE: The EasyGuide™ Neuro Image-Guided Surgery System. *Neurosurgery* 40: 1092-1095, 1997.
35. Alleyne C, Olson JJ, Bakay RAE, Fox T, Crocker I, Cotsonis G: Stereotactic Radiosurgery of Malignant and Benign Intracranial Lesions Utilizing a Patient Rotator. *Radiation Oncology Investigations* 5: 20-30, 1997.
36. Chen W, He J, Olson JJ, Lu R: Carboplatin-loaded PLGA microspheres for intracerebral implantation: in vivo characterization. *Drug Delivery* 4: 301-311, 1997.
37. Olson JJ, Barnett D, Yang J, Assietti R, Cotsonis G, James CD: Gene Amplification as a Prognostic Factor in Primary Brain Tumors. *Clinical Cancer Research* 4: 215-222, 1998.
38. Alleyne CH, Jr., Hunter S, Olson JJ, Barrow DL: Lipomatous neurocytoma of the posterior fossa with divergent differentiation. *Neurosurgery* 42: 639-643, 1998.
39. Chen W, He J, Olson JJ, Lu R: Brain tissue reaction following intracerebral injection of free or liposomally encapsulated BSH. *Drug Delivery* 5: 1-10, 1998.
40. Shoup TM, Olson JJ, Hoffman JM, Votaw J, Eshima D, Camp VM, Votaw D, Goodman MM: Synthesis and evaluation of [¹⁸F]-1-amino-3-fluoro-cyclobutane-1-carboxylic acid to image brain tumors. *J Nucl Med* 40: 331-338, 1999.
41. Alleyne CH, He J, Yang J, Hunter SB, Cotsonis G, James CD, Olson JJ: Analysis of Cyclin Dependent Kinase Inhibitors in Malignant Astrocytomas. *Int J Oncol* 14: 1111-1116, 1999.

42. James CD, Galanis E, Frederick L, Kimmel DW, Cunningham JM, Atherton-Skaff PJ, O'Fallon JR, Jenkins RB, Buckner JC, Hunter SB, Olson JJ, Scheithauer BW: Tumor suppressor gene alterations in malignant gliomas: Histopathological associations and prognostic evaluation. *Int J Oncol* 15: 547-53, 1999.
43. Yung WKA, Prados MD, Yay-Tur R, Rosenfield SS, Brada M, Friedman HS, Albright R, Olson J, Chang SM, O'Neill AM, Friedman AH, Bruner , Yue N, Dugan M, Zaknoen S, Levin VA: Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. *J Clin Oncol* 17: 2762-2771, 1999.
44. Bingaman KD, Alleyene C, Olson JJ: Intracranial extraskeletal mesenchymal chondrosarcoma. *Neurosurgery* 46: 207-212, 2000.
45. Schinazi RF, Hurwitz SJ, Liberman I, Juodawkis A, Shi J, Liotta DC, Coderre J, Olson J: β -5-o-Carboranyl-2'-deoxyuridine for the treatment of malignant brain tumors. *Clin Cancer Res* 6: 725-730, 2000.
46. Trounce I, Schmiedel J, Yen H-C, Hosseini S, Brown MD, Olson JJ, Wallace DC: Cloning of neuronal mtDNA variants in cultured cells by synaptosome fusion with mtDNA-less cells. *Nucleic Acids Research* 28: 2164-2170, 2000.
47. Houston SC, Crocker IR, Brat DJ, Olson JJ: Extraneural Metastatic Glioblastoma After Interstitial Brachytherapy. *Int J Radiat Oncol Biol Phys* 48: 831-836, 2000.
48. Yung WKA, Albright RE, Olson J, Fredericks R, Fink K, Prados M, Spence A, Hohl RJ, Shapiro W, Glantz M, Greenberg H, Selker RG, Vick NA, Rampling R, Friedman H, Phillips R, Bruner J, Yue N, Osaba D, Zaknoen S, Levin VA: A phase II study of temozolomide vs. procarbazine in patients with glioblastoma at first relapse. *Br J Cancer* 83: 588-93, 2000.
49. Sharara N, Muller S, Olson J, Grist WJ, Grossniklaus HE: Sinonasal undifferentiated carcinoma with orbital invasion. *Ophthalmic Plastic and Recon Surg* 4: 288-292, 2001
50. Stubbs J, Frankel R, Schultz K, Crocker I, Dillehay D, Olson JJ: Pre-clinical evaluation of a novel device for delivering brachytherapy to resected brain tumor cavity margins. *J Neurosurg* 96: 335-343, 2002.
51. Hunter S, Young A, Olson J, Brat DJ, Bowers G, Wilcox JN: Differential expression between pilocytic and anaplastic astrocytoma: identification of apolipoprotein D as a marker for low-grade, non-infiltrating primary CNS neoplasms. *J Neuropathol Exp Neurol* 61: 275-281, 2002.
52. McConathy J, Martello L, Malveaux EJ, Camp VM, Simpson NE, Simpson, Bowers GD, Olson, JJ, Goodman MM: Radiolabeled amino acids for tumor imaging with PET: Radiosynthesis and biological evaluation of 2-amino-3-[¹⁸F]fluoro-2-methylpropanoic acid and 3-[¹⁸F]fluoro-2-methyl-2-(methylamino)propanoic acid. *J Med Chem* 45: 2240-2249, 2002.

53. Selker RG, Shapiro W, Burger P, Blackwood, Deutsch M, Arena V, Van Gilder JC, Wu J, Malkin M, Mealey J, Jr, Neal J, Olson J, Robertson JT, Barnett G, Bloomfield S, Albright R, Hochberg FH, Heisigner E, Green S: The Brain Tumor Cooperative Group NIH Trial 87-01: A randomized comparison of surgery, external radiotherapy and BCNU v. surgery, interstitial radiotherapy boost, external radiation therapy and BCNU. *Neurosurgery* 51:343-357, 2002.
54. Mayr MT, Crocker IR, Butker EK, Williams WH, Cotsonis GA, Olson JJ: Results of interstitial brachytherapy for malignant brain tumors. *Int J Oncol.* 21:817-823, 2002.
55. Martarello L, McConathy J, Camp VM, Malveaux EJ, Simpson NE, Simpson CP, Olson JJ, Gowers GD, Goodman MM: Synthesis of *syn*- and *anti*-1-Amino-3-[¹⁸F]fluoromethyl-cyclobutane-1-carboxylic Acid (FMACBC), Potential PET Ligands for Tumor Detection. *J Med Chem* 45: 2250-2259, 2002.
56. Gilbert MR, Friedman HS, Kuttlesch JF, Prados MD, Olson JJ, Reaman GH, Zakonen SL: A Phase II Study of Temozolomide in Patients With Newly Diagnosed, Supratentorial Malignant Glioma Prior to Radiation Therapy. *Neuro-Oncology*: 261-267, October, 2002.
57. Lonser RR, Walbridge S, Vortmeyer AO, Pack SD, Nguyen TT, Gogate N, Olson JJ, Akbasak A, Bobo RH, Goffman T, Zhuang Z, Oldfield EH: Induction of glioblastoma multiforme in nonhuman primates after therapeutic doses of fractionated whole brain radiation therapy. *J Neurosurg* 97(6): 1378-1389, 2002.
58. Zabramski JM, Whiting D, Darouiche RO, Horner TG, Olson J, Robertson C, Hamilton AJ: Efficacy of antimicrobial-impregnated external ventricular drainage catheters: A prospective randomized, controlled trial. *J Neurosurg.* 98(4):725-730, 2003.
59. Bowers G, He J, Schultz K, Olavarria G, Maneval D, Olson JJ: Efficacy of adenoviral p53 delivery with SCH58500 in the intracranial 9L and RG2 models. *Frontiers in Bioscience.* 8:a54-61, May 1, 2003.
60. Olivi A, Grossman SA, Tatter S, Barker F, Judy K, Olson J, Bruce J, Hilt D, Fisher J, Piantadosi S: Dose escalation of Carmustine in surgical implanted polymers in patients with recurrent malignant glioma: A New Approaches to Brain Tumor Therapy CNS Consortium Trial. *J Clinical Oncology* 21(9): 1845-1849, 2003.
61. McConathy J, Martarello L, Malveaux EJ, Camp VM, Simpson NE, Simpson CP, Bowers GD, Zhang Z, Olson JJ, Goodman MM: Synthesis and evaluation of 2-amino-4-[(18)F]fluoro-2-methylbutanoic acid (FAMB): relationship of amino acid transport to tumor imaging properties of branched fluorinated amino acids. *Nucl Med Biol* 30(5): 477-490, 2003.
62. Hunter SB, Brat DJ, Olson JJ, von Deimling A, Zhou W, Ven Meir EG: Alterations in molecular pathways in diffusely infiltrating glial neoplasms: application to tumor classification and anti-tumor therapies. *Int J Oncol.* 23(4):857-869, 2003.
63. Tatter SB, Shaw EG, Rosenblum ML, Karvelis KC, Kleinberg L, Weingart J, Olson JJ, Crocker IR, Brem S, Pearlman JL, Fisher JD, Carson KA, Grossman SA: An inflatable

- balloon catheter and liquid ¹²⁵I radiation source (Gliasite Radiation Therapy System) for treatment of recurrent glioma: multicenter and feasibility study. *J Neurosurg* 99:297-303, 2003.
64. Narayan P, Crocker I, Elder E, Olson JJ: Safety and efficacy of concurrent interstitial radiation and hyperthermia in the treatment of progressive malignant brain tumors. *Oncology Reports*. 11: 97-103, 2004.
 65. Schinazi RF, Hurwitz SJ, Liberman I, Glazkova Y, Mourier NS, Olson J, Keane T: Tissue disposition of 5-o-carboranyluracil – A novel agent for boron neutron capture therapy of prostate cancer. *Nucleosides, Nucleotides, and Nucleic Acids* 23: 291-306, 2004.
 66. Junge CE, Lee CJ, Hubbard KB, Zhang Z, Olson JJ, Hepler JR, Brat DJ, Traynelis ST: Protease-activated receptor-1 (PAR1) in human brain: localization and functional expression in astrocytes. *Experimental Neurology* 188: 94-103, 2004.
 67. Olson JJ, James D, Lawson D, Hunter S, Tang G, Billingsley J: Correlation of the response of recurrent malignant gliomas treated with interferon with tumor interferon α gene content. *Int J Oncol* 25: 419-427, 2004.
 68. Phuphanich S, Brat DJ, Olson JJ: Delivery systems and molecular targets of mechanism-based therapies for GBM. Review. *Expert Rev Neurother* 4(4):649-663, 2004.
 69. Chiocca EA, Abbed KM, Tatter S, Louis DN, Hochberg FH, Barker F, Kracher J, Grossman SA, Fisher JD, Carson K, Rosenblum M, Mikkelsen T, Olson J, Markert J, Rosenfeld S, Nabors LB, Brem S, Phuphanich S, Freeman S, Kaplan R, Zwiebel J. Related Articles, Links A Phase I Open-Label, Dose-Escalation, Multi-Institutional Trial of Injection with an E1B-Attenuated Adenovirus, ONYX-015, into the Peritumoral Region of Recurrent Malignant Gliomas, in the Adjuvant Setting. *Mol Ther* 10(5):958-66, 2004.
 70. Post DE, Devi NS, Li Z, Brat DJ, Kaur B, Nicholson A, Olson JJ, Zhang Z and Van Meir EG Cancer therapy with a replicating oncolytic adenovirus targeting the hypoxic microenvironment of tumors. *Clin Cancer Res* 10(24): 8603-8612, 2004.
 71. Phuphanich S, Brat DJ, Olson JJ: Delivery systems and molecular targets of mechanism-based therapies for GBM. *Expert Review of Neurotherapeutics*. 4(4):649-63, 2004.
 72. Tan C, de Noronha RG, Roecker AJ, Pyrzynska B, Khwaja F, Zhang Z, Zhang H, Teng Q, Nicholson AC, Giannakakou P, Zhou W, Olson JJ, Pereira MM, Nicolaou KC, and Van Meir EG: Identification of a novel small molecule inhibitor of the hypoxia-inducible factor-1 (HIF-1) pathway. *Cancer Res* 65(2): 605-612, 2005.
 73. Hunter SB, Varma V, Shehata B, Nolen JDL, Cohen C, Olson JJ, Ou CY: Apolipoprotein D expression in primary brain tumors: Analysis by quantitative RT-PCR in formalin-fixed, paraffin-embedded tissue. *J Histochem Cytochem* 53:963-969, 2005.

74. Macdonald DR, Kiebert G, Prados M, Yung A, Olson J: Benefit of temozolomide compared to procarbazine in treatment of glioblastoma multiforme at first relapse: effect on neurological functioning, performance status, and health related quality of life. *Cancer Investigation*. 23(2):138-44, 2005.
75. Khwaja FW, Nolen JD, Mendrinos SE, Lewis MM, Olson JJ, Pohl J, Van Meir EG, Ritchie JC, Brat DJ: Proteomic analysis of cerebrospinal fluid discriminates malignant and nonmalignant disease of the central nervous system and identifies specific protein markers. *Proteomics* 6:6277-87, 2006
76. Kang SH, Cho HT, Devi S, Zhang Z, Escuin D, Liang Z, Mao H, Brat DJ, Olson JJ, Simons JW, LaVallee TM, Giannakakou P, Van Meir EG, Shim H. Antitumor Effect of 2-Methoxyestradiol in a Rat Orthotopic Brain Tumor Model. *Cancer Res* 66: 11991-1997, 2006.
77. Chhabra VS, Zhang J, Olson JJ: Association between an arachnoid cyst and intracranial aneurysms misdiagnosed as a cystic tumor with a mural nodule. *Neurosurgical Focus* 22: E3, 2007
78. Khwaja FW, Reed MS, Olson JJ, Schmotzer BJ, Gillespie GY, Guha A, Groves MD, Kesari S, Pohl J and Van Meir EG: Proteomic identification of biomarkers in the cerebrospinal fluid (CSF) of astrocytoma patients. *J Proteome Res* 6, 559-570, 2007.
79. Tehrani M, Friedman T, Olson JJ, Brat DJ. Intravascular thrombosis in central nervous system malignancies: potential role in astrocytoma progression to glioblastoma. *Brain Pathol* 18: 164-171, 2008.
80. Olson JJ, Zhang Z, Dillehay D, Stubbs J: Assessment of a balloon-tipped catheter modified for intracerebral convection-enhanced delivery. *J Neuro-oncology* 89 : 159 – 168, 2008
81. Yu W, Williams L, Malveaux E, Camp VM, Olson JJ, Goodman MM: Synthesis and evaluation of [123I] labeled iodovinyl amino acids syn-, anti-1-amino-3-[2-iodoethenyl]-cyclobutane-1-carboxylic acid, and 1-amino-3-iodomethylene-cyclobutane-1-carboxylic acid as potential SPECT brain tumor imaging agents. *Bioorganic & Medicinal Chemistry Letters*. 18(4):1264-8, 2008.
82. Grossman SA, Olson J, Batchelor T, Peereboom D, Lesser G, Desideri S, Ye X, Hammour T, Supko JG. New Approaches to Brain Tumor Therapy CNS Consortium. Effect of phenytoin on celecoxib pharmacokinetics in patients with glioblastoma. *Neuro-Oncology*. 10(2):190-8, 2008.
83. Phuphanich S, Carson KA, Grossman SA, Lesser G, Olson J, Mikkelsen T, Desideri S, and Fisher JD: Phase I safety study of escalating doses of atrasentan in adults with recurrent malignant glioma. *Neuro-oncology* 10: 617-23, 2008.
84. Olson JJ, Ryken TC: Guidelines for the Treatment of Newly Diagnosed Glioblastoma: Introduction. *Journal of Neuro-oncology* 89: 255-258, 2008.
85. Mukundan S, Holder CA, Olson JJ: Neuroradiological Assessment of Newly Diagnosed Glioblastoma. *Journal of Neuro-oncology* 89: 259-269, 2008.

86. Ryken TC, Frankel B, Julien T, Olson JJ: Surgical Management of Newly Diagnosed Glioblastoma in Adults: Role of Cytoreductive Surgery. *Journal of Neuro-oncology* 89: 271-286, 2008.
87. Brat, DJ, Prayson RA, Ryken TC, Olson JJ: Diagnosis of Malignant Glioma: Role of Neuropathology. *Journal of Neuro-oncology* 89: 287-311, 2008.
88. Buatti J, Ryken, R, Smith MC, Sneed P, Suh J, Mehta M, Olson JJ: Radiation Therapy of Pathologically Confirmed Newly Diagnosed Glioblastoma in Adults. *J Neuro-oncology* 89: 313-337, 2008.
89. Fadul CE, Wen PY, Kim L, Olson JJ: Cytotoxic Chemotherapeutic Management of Newly Diagnosed Glioblastoma Multiforme. *J Neuro-oncology* 89: 339-357, 2008.
90. Olson JJ, McKenzie E, Skurski-Martin M, Zhang Z, Brat D, Phuphanich S. Phase I Analysis of BCNU-impregnated Biodegradable Polymer Wafers Followed by Systemic Interferon alfa-2b in Adults With Recurrent Glioblastoma Multiforme. *J Neuro-oncology* 90: 293-300, 2008.
91. Blakeley JO, Olson J, Grossman SA, He X, Weingart J, Supko JG: Effect of blood brain barrier permeability in recurrent high grade gliomas on the intratumoral pharmacokinetics of methotrexate: a microdialysis study. *J Neuro-oncology* 91: 51-58, 2008.
92. Roger McLendon, Allan Friedman, Darrell Bigner, Erwin G. Van Meir, Daniel J. Brat, Gena M. Mastrogianakis, Jeffrey J. Olson, et al: The Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. *Nature* (On line publication September 4, 2008), 455: 1061-8, 2008.
93. Kaur B, Sandberg E, Devi N, Zhang Z, Klenotic P, Febbraio M, Shim H, Mao H, Cork S, Silverstein R, Brat D, Olson J, Van Meir E: Vasculostatin inhibits intracranial glioma growth and negatively regulates in vivo angiogenesis through a CD36-dependent mechanism. *Cancer Research* 69:1212–20, 2009.
94. Rong Y, Chen G, Tucker-Burden C, Durden D, Van Meir E, Olson JJ; Mackman N, Brat D: EGFR and PTEN Modulate Tissue factor Expression in Glioblastoma Through JunD/AP-1 Transcriptional Activity. *Cancer Res* 69: 2540-2549, 2009.
95. Olson JJ, Fadul CE, Brat DJ, Mukundan S, Timothy C. Ryken TC: Management of Newly Diagnosed Glioblastoma: Guidelines Development, Value and Applications. *J Neuro-oncol* 93: 1-23, 2009..
96. Bellail AC, Tse MCL, Song JH, Phuphanich S, Olson JJ, Sun SY, Hao C: DR5-mediated DISC controls caspase-8 cleavage and initiation of apoptosis in human glioblastomas. *J. Cell. Mol. Med* 14: 1303-17, 2010.
97. Yu W, McConathy J, Williams L, Vernon M. Camp VM, Malveaux EJ, Zhang Z, Olson JJ, Goodman MM: Synthesis, Radiolabeling, and Biological Evaluation of (R)- and (S)-2-Amino-3-[18F]Fluoro-2-Methylpropanoic Acid (FAMP) and (R)- and (S)-3-

[18F]Fluoro-2-Methyl-2-N-(Methylamino)propanoic Acid (NMeFAMP) as Potential PET Radioligands for Imaging Brain Tumors. *J Med Chem* 53: 876–886, 2010.

98. Gaspar LE, Mehta MP, Patchell RA, Burri SH, Robinson PD, Morris RE, Ammirati M, Andrews DW, Asher AL, Cobbs CS, Kondziolka D, Linskey ME, Loeffler JS, McDermott M, Mikkelsen T, Olson JJ, Paleologos NA, Ryken TC, Kalkanis SN: The role of whole brain radiation therapy in the management of newly diagnosed brain metastases: A systematic review and evidence-based clinical practice guideline. *J Neuro-oncology* 96: 17-32, 2010.
99. Kalkanis SN, Kondziolka D, Gaspar LE, Burri SH, Asher AL, Cobbs CS, Ammirati M, Robinson PD, Andrews DW, Loeffler JS, McDermott M, Mehta MP, Mikkelsen T, Olson JJ, Paleologos NA, Patchell RA, Timothy C. Ryken TC, Linskey ME: The role of surgical resection in the management of newly diagnosed brain metastases: A systematic review and evidence-based clinical practice guideline. *J Neuro-oncology* 96: 33-43, 2010.
100. Linskey ME, Andrews DW, Asher AL, Burri SH, Douglas Kondziolka D, Robinson PD, Ammirati M, Cobbs CS, Gaspar LE, Loeffler JS, McDermott M, Mehta MP, Mikkelsen T, Olson JJ, Paleologos NA, Patchell RA, Ryken TC, Steven N. Kalkanis SN: The role of stereotactic radiosurgery in the management of patients with newly diagnosed brain metastases: A systematic review and evidence-based clinical practice guideline. *J Neuro-oncology* 96: 45-68, 2010.
101. Mehta MP, Paleologos NA, Mikkelsen T, Robinson PD, Ammirati M, Andrews DM, Asher AL, Burri SH, Cobbs CS, Gaspar LE, Kondziolka D, Linskey ME, Loeffler JS, McDermott M, Olson JJ, Patchell RA, Ryken TC, Kalkanis SN: The role of chemotherapy in the management of newly diagnosed brain metastases: A systematic review and evidence-based clinical practice guideline. *J Neuro-oncology* 96: 71-83, 2010.
102. Ammirati M, Cobbs CS, Linskey ME, Paleologos NA, Ryken TC, Burri SH, Asher AL, Loeffler JS, Robinson PD, Andrews DW, Gaspar LE, Kondziolka D, McDermott M, Mehta MP, Mikkelsen T, Olson JJ, Patchell RA, Kalkanis SN: The role of retreatment in the management of recurrent / progressive brain metastases: A systematic review and evidence-based clinical practice guideline. *J Neuro-oncology* 96: 85-96, 2010.
103. Mikkelsen T, Paleologos NA, Robinson PD, Ammirati M, Andrews DM, Asher AL, Burri SH, Cobbs CS, Gaspar LE, Kondziolka D, Linskey ME, Loeffler JS, McDermott M, Mehta MP, Olson JJ, Patchell RA, Ryken TC, Kalkanis SN: The role of prophylactic anticonvulsants in the management of brain metastases: A systematic review and evidence-based clinical practice guideline. *J Neuro-oncology* 96: 97-102, 2010.
104. Ryken TR, McDermott M, Robinson PD, Ammirati M, Andrews DW, Asher AL, Burri SH, Cobbs CS, Gaspar LE, Kondziolka D, Linskey ME, Loeffler JS, Mehta MP, Mikkelsen T, Olson JJ, Paleologos NA, Patchell RA, Kalkanis SN: The role of steroids in the management of brain metastases: A systematic review and evidence-based clinical practice guideline. *J Neuro-oncology* 96: 103-114, 2010.

105. Olson JJ, Paleologos NA, Gaspar LE, Robinson PD, Morris RE, Ammirati M, Andrews DW, Asher AL, Burri SH, Cobbs CS, Kondziolka D, Linskey ME, Loeffler JS, McDermott M, Mehta MP, Mikkelsen T, Patchell RA, Ryken TC, Kalkanis SN: The role of emerging and investigational therapies for metastatic brain tumors: A systematic review and evidence-based clinical practice guideline of selected topics. *J Neuro-oncology* 96: 115-142, 2010.
106. Phuphanich S, Supko JG, Carson KA, Grossman SA, Nabors LB, Mikkelsen T, Lesser G, Rosenfeld R, Desideri S, Olson JJ: Phase 1 clinical trial of bortezomib in adults with recurrent malignant glioma. *J Neurooncol*, 100: 95-103, 2010.
107. Schuette AJ, Taub JS, Hadjipanayis CG, Olson JJ: The Role of Biopsy in Patients with Acute Progressive Neurological Decline and Absence of Mass Lesion. *Neurology* 75: 419-24, 2010.
108. Roberts CC, Daffner RH, Weissman BN, Bancroft L, Bennett DL, Blebea JS, Bruno MA, Fries IB, Germano IM, Holly L, Jacobson JA, Luchs JS, Morrison WB, Olson JJ, Payne WK, Resnik CS, Schweitzer ME, Seeger LL, Taljanovic M, Wise JN, Lutz ST: ACR Appropriateness Criteria® on Metastatic Bone Disease. *J Am Coll Radiol* 7:400-409, 2010.
109. Yan D., Ng WL., Zhang X, Wang P, Zhang Z, Mo YY, Mao H, Hao C, Olson JJ, Curran WJ, Wang Y: Targeting DNA-PKcs and ATM with miR-101 Sensitizes Tumors to Radiation. *PLoS ONE* 5 (e11397): 1-8, 2010.
110. Van Meir EG, Hadjipanayis CG, Norden AD, Shu HK, Wen PY, Olson JJ: Exciting New Advances in Neuro-oncology: The Avenue to a Cure for Malignant Glioma. *CA: A Cancer J for Clinicians* 60: 166-193, 2010.
111. Raore B, Schniederjan M, Prabhu R, Brat DJ, Shu HK, Olson JJ: Metastasis Infiltration: An investigation of the post operative brain-tumor interface. *International Journal of Radiation Oncology, Biology and Physics* 81: 1075-1080, 2011.
112. Egan KM, Thompson LB, Nabors LB, JJ Olson, DJ Brat, LaRocca RV, Brem S, Moots PL, Madden MH, Browning JE, Chen YA: Cancer susceptibility variants and the risk of adult glioma in a US case-control study. *J Neuro-Oncology* 104: 535-42, 2011.
113. Ding L, Yuan C, Wei F, Wang G, Zhang J, Bellail AC, Zhang Z, Olson JJ, Hao C: Cisplatin Restores TRAIL Apoptotic Pathway in Glioblastoma-Derived Stem Cells through Up-regulation of DR5 and Down-regulation of c-FLIP. *Cancer Invest* 29: 511-520, 2011.
114. Tanaka T, Olson JJ: Case Study: Brain Abscess Without an Obvious Source of Infection. *J Med Assoc Georgia* 100: 25, 2011.
115. Qi L, Bellail AC, Rossi MR, Zhang Z, Pang H, Hunter S, Cohen C, Moreno CS, Olson JJ, Li S, Hao C: Heterogeneity of primary glioblastoma cells in the expression of

- caspase-8 and the response to TRAIL-induced apoptosis. *Apoptosis* 16: 1150-1164, 2011.
116. Bellail AC, Olson JJ, Yang X, Chen ZJ, Hao C: A-20 ubiquitin ligase-mediated polyubiquitination of RIP1 inhibits caspase-8 cleavage and TRAIL-induced apoptosis in glioblastoma. *Cancer Discovery* 2: 140-155, 2012.
 117. Zheng Z, Ng WL, Zhang X, Olson JJ, Hao C, Curran WJ, Wang Y: RNAi-mediated targeting of non-coding and coding sequences in DNA repair gene messages efficiently radiosensitizes human tumor cells. *Cancer Research*. 72: 1221-8, 2012
 118. Wei F, Liu Y, Bellail AC, Olson JJ, Sun SY, Lu G, Ding L, Changji Yuan C, Wang G, Hao C: K-Ras mutation-mediated IGF-1-induced feedback ERK activation contributes to the rapalog resistance in pancreatic ductal adenocarcinomas. *Cancer Letters* 322: 58-69, 2012
 119. Nabors LB, Mikkelsen T, Hegi ME, Ye X, Batchelor T, Lesser G, Peereboom D, Rosenfeld MR, Olson J, Brem S, Fisher JD, Grossman SA: Safety Run-in and Randomized Phase II Study of Cilengitide Combined with Chemoradiation for Newly Diagnosed Glioblastoma (NABTT 0306). *Cancer*, 118: 5601-7, 2012.
 120. Xiao Y, Decker PA, Rice T, McCoy LS, Smirnov I, Patoka JS, Hansen H, Wiemels JL, Tihan T, Prados M, Chang S, Berger M, Kosel ML, Fridley BL, Lachance DH, O'Neill BP, Buckner JC, Burch P, Thompson RC, Nabors LB, Olson JJ, Brem S, Madden MH, Browning JE, Wiencke JK, Egan KM, Jenkins RB, Wrensch MR: SSBP2 variants impact survival in uniformly-treated glioblastoma patients. *Clin Cancer Res*18: 3154-62, 2012.
 121. Wang L, Chen D, Olson J, Ali S, Fan T, and Mao M: Re-examining tumor-induced alterations in hemodynamic responses of BOLD fMRI: implications in presurgical brain mapping. *Acta Radiologica*, 53: 802-11, 2012.
 122. Prabhu R, Shu HK, Hadjipanayis C, Dhabaan A, William Hall W, Raore B, Olson J, Curran W, Nelson Oyesiku, N, Ian Crocker I: Current Dosing Paradigm for Stereotactic Radiosurgery Alone After Surgical Resection of Brain Metastases Needs to Be Optimized for Improved Local Control. *Int J Radiation Oncol Biol Phys* 83 e61-e66, 2012.
 123. Grossmann KF, Colman H, Akerley WA, Glantz M, Matsuoko Y, Beelen AP, Yu M, De Groot JF, Aiken RD, Olson JJ, Evans BA, Jensen RL: Phase I trial of verubulin (MPC-6827) plus carboplatin in patients with relapsed glioblastoma multiforme. *J Neuro-oncol* 110(2):257-64, 2012.

124. Qi Q. He K. Yoo MH. Chan CB. Liu X. Zhang Z. Olson JJ. Xiao G. Wang L. Mao H. Fu H. Tao H. Ramalingam SS. Sun SY. Mischel PS. Ye K: Acridine yellow G blocks glioblastoma growth via dual inhibition of epidermal growth factor receptor and protein kinase C kinases. *Journal of Biological Chemistry*. 287(9):6113-27, 2012.
125. Zheng Z. Ng WL. Zhang X. Olson JJ. Hao C. Curran WJ. Wang Y: RNAi-mediated targeting of noncoding and coding sequences in DNA repair gene messages efficiently radiosensitizes human tumor cells. *Cancer Research*. 72(5):1221-8, 2012.
126. Egan KM. Nabors LB. Olson JJ. Monteiro AN. Browning JE. Madden MH. Thompson RC: Rare TP53 genetic variant associated with glioma risk and outcome. *Journal of Medical Genetics*. 49(7):420-1, 2012.
127. Anic GM. Thompson RC. Nabors LB. Olson JJ. Browning JE. Madden MH. Murtagh FR. Forsyth PA. Egan KM: An exploratory analysis of common genetic variants in the vitamin D pathway including genome-wide associated variants in relation to glioma risk and outcome. *Cancer Causes & Control*. 23(9):1443-9, 2012.
128. Wei L. Hong S. Yoon Y. Hwang SN. Park JC. Zhang Z. Olson JJ. Hu XP. Shim H: Early prediction of response to Vorinostat in an orthotopic rat glioma model. *NMR in Biomedicine*. 25(9):1104-11, 2012.
129. Yin S. Kaluz S. Devi NS. Jabbar AA. de Noronha RG. Mun J. Zhang Z. Boreddy PR. Wang W. Wang Z. Abbruscato T. Chen Z. Olson JJ. Zhang R. Goodman MM. Nicolaou KC. Van Meir EG: Arylsulfonamide KCN1 inhibits in vivo glioma growth and interferes with HIF signaling by disrupting HIF-1 interaction with cofactors p300/CBP. *Clinical Cancer Research*. 18(24):6623-33, 2012.
130. Wang L, Chen D, Yang X, Olson JJ, Gopinath K, et al. Group Independent Component Analysis and Functional MRI Examination of Changes in Language Areas Associated with Brain Tumors at Different Locations. *PLoS ONE* 8(3): e59657. doi:10.1371/journal.pone.0059657, 2013.
131. Amankwah EK. Thompson RC. Nabors LB. Olson JJ. Browning JE. Madden MH. Egan KM: SWI/SNF gene variants and glioma risk and outcome. *Cancer Epidemiology*. 37(2):162-5, 2013.

132. Appin CL, Gao J, Chisolm C, Torian M, Alexis J, Vincentelli C, Schniederjan MJ, Hadjipanayis C, Olson JJ, Hunter S, Hao C, Brat DJ: Glioblastoma with oligodendroglioma component (GBM-O): molecular genetic and clinical characteristics. *Brain Pathology*. 23(4):454-61, 2013.
133. Press RH, Prabhu RS, Appin CL, Brat DJ, Shu HK, Hadjipanayis C, Olson JJ, Oyesiku NM, Curran WJ, Crocker I: Outcomes and Patterns of Failure for Grade II Meningioma Treated With Reduced Margin Intensity Modulated Radiation Therapy. *Int J Radiat Oncol Biol Phys*. 88:1004-10, 2014.
134. Olson JJ: Glioblastoma at progression: therapy of a challenging problem addressed candidly with evidence-based techniques. *Journal of Neuro-oncology*, 118: 427-428, 2014
135. Olson JJ, Ryken, TC, Kalkanis, SN: The Management of Progressive Glioblastoma: A Systematic Review and Evidence-Based Clinical Practice Guideline: Introduction and Rationale. *Journal of Neuro-oncology*, 118: 429-434, 2014
136. Ryken CR, Aygun N, Morris J, Schweizer M, Nair R, Spracklen C, Kalkanis SH, Olson JJ: The Role of Imaging in the Management of Progressive Glioblastoma. *Journal of Neuro-oncology*, 118: 435-460, 2014.
137. Brat DJ, Ryken TC, Kalkanis SN, Olson JJ: The Role of Neuropathology in the Management of Progressive Glioblastoma. *Journal of Neuro-oncology*, 118: 461-478, 2014.
138. Ryken TC, Kalkanis SN, Buatti JM, Olson JJ: The Role of Cytoreductive Surgery in the Management of Progressive Glioblastoma. *Journal of Neuro-oncology*, 118: 479-488, 2014.
139. Ryu S, Buatti JM, Morris A, Kalkanis SN, Ryken TC, Olson JJ: The Role of Radiotherapy in the Management of Progressive Glioblastoma. *Journal of Neuro-oncology*, 118: 489-499, 2014.
140. Olson JJ, Nayak L, Ormond DR, Wen PY, Kalkanis SN: The Role of Cytotoxic Chemotherapy in the Management of Progressive Glioblastoma. *Journal of Neuro-oncology*, 118: 501-555, 2014.

141. Olson JJ, Nayak L, Ormond DR, Wen PY, Kalkanis SN: The Role of Targeted Therapies in the Management of Progressive Glioblastoma. *Journal of Neuro-oncology*, 118: 557-599, 2014.
142. Owonikoko T, Arbiser J, Zelnak A, Shu HK, Shim H, Robin A, Kalkanis SN, Whitsett T, Salhia B, Tran N, Ryken T, Moore M, Egan K, Olson JJ: Current approaches to the treatment of metastatic brain tumours. *Nature Rev Clin Oncol*, 11, 203–222, 2014.
143. Shim H, Li W, Holder CA, Guo Y, Hu XP, Miller AH, and Olson JJ: Use of high resolution volumetric MR spectroscopic imaging in assessing treatment response of GBM to an HDAC inhibitor. *American Journal of Roentgenology*. 203:W158-W165. DOI 10.2214/AJR.14.12518, 2014.
144. Bellail AC, Olson JJ and Hao C: SUMO1 modification stabilizes CDK6 protein and drives the cell cycle and glioblastoma progression. *Nature Communications*, June 23, 2014, 5:4234 | DOI: 10.1038/ncomms5234.
145. Patel KR, Prabhu RS, Kandula S, Oliver DE, Kim S, Hadjipanayis C, Olson JJ, Oyesiku N, Curran WJ, Khan MK, Shu HK, Crocker I. Intracranial control and radiographic changes with adjuvant radiation therapy for resected brain metastases: whole brain radiotherapy versus stereotactic radiosurgery alone. *J Neurooncol*: 120:657-63, 2014. PMID: 25189789
146. Linskey ME, Olson JJ, Mitchell LS, Kalkanis SN: Clinical practice guidelines in the AANS/CNS Section on Tumors: Past, Present and Future Directions. *Journal of Neuro-Oncology*: 119: 557-568, 2014.
147. Zhu D, Li C, Swanson AM, Villalba RM, Guo J, Zhang Z, Matheny S, Murakami T, Stephenson JR, Daniel S, Fukata M, Hall RA, Olson JJ, Neigh GN, Smith Y, Rainnie DG, and Van Meir EG: BAI1 regulates spatial learning and synaptic plasticity in the hippocampus. *Journal of Clinical Investigation*: *In Press*, February 10, 2015.
148. Eaton BR, LaRiviere MJ, Kim S, Prabhu R, Patel K, Kandula S, Oyesiku N, Olson J, Curran W, Shu H, Crocker I: Hypofractionated Radiosurgery has a Better Safety Profile than Single Fraction radiosurgery for Large Resected Brain Metastases. *Journal of Neuro-oncology*. *In Press*, April 3rd 2015.

149. Kleinberg LR, Stieber V, Mikkelsen T, Judy K, Weingart J, Barnett G, Olson J, Desideri S, Ye X, Grossman S.: Outcome of Adult Brain Tumor Consortium (ABTC) Prospective Dose Finding Trials of I-125 Balloon Brachytherapy in High Grade Gliomas: Challenges in clinical trial design and technology development when MRI treatment effect and recurrence appear similar. *Journal of Radiation Oncology*, *in press*, July, 2015.
150. Patel KR, Burri SH, Asher AL, Crocker IR, Fraser RW, Zhang C, Chen Z, Kandula S, Zhong J, Press RH, Olson JJ, Oyesiku NM, Wait SD, Curran WJ, Shu HK, Prabhu RS. Comparing Pre-operative to Post-operative Stereotactic Radiosurgery for Resectable Brain Metastases: A Multi-institutional Analysis. *Neurosurgery*. *In press*, September 11, 2015.

Texts

1. Skull Base Surgery: Basic Techniques. Moore CE, Olson JJ (eds.), Plural Publishing, San Diego, CA, 2010.

Review Articles

1. Olson JJ: Recurrent gliomas. *Neurosurgical Consultations* Vol. 3(18), 1992.
2. James CD, Olson JJ: Molecular genetics and molecular biology advances in brain tumors. *Current Opinion in Oncology* 8: 188-195, 1996.
3. Suh DY, Olson JJ: Management of recurrent malignant primary brain tumors. Part I: Etiology, clinical diagnosis, and treatment options. *Contemporary Neurosurgery* 20 (11), June, 1998.
4. Suh DY, Olson JJ: Management of recurrent malignant primary brain tumors. Part II: Chemotherapy, radiation and radiosurgery, brachytherapy, and decision making. *Contemporary Neurosurgery* 20 (12), June, 1998.
5. Olson JJ: Neurosurgical Advances in the Treatment of Brain Tumors. *Current Oncology Reports* 2: 434-437, 2000.
6. Narayan P, Olson JJ: Management of Anaplastic Astrocytomas. *Contemporary Neurosurgery* 23 (24), 2001.

Book Chapters

1. Morgan JS, Olson JJ: Steroid hormones and meningiomas. *Meningiomas and Their Surgical Management*, H.H. Schmidek (ed.), W.B. Saunders, Philadelphia, pp. 48-55. 1991.

2. Olson JJ, Reisner A: Craniotomy for Brain Tumor in M.F. Lubin, K. Walker, R.B. Smith, III (eds), *Medical Management of the Surgical Patient*, 3rd Ed. J.B. Lippincott, Philadelphia, 1994.
3. Olson JJ, Rossi J: Radiobiology of the Central Nervous System. Tindall GT, Cooper P, Barrow D (eds) *Practice of Neurosurgery*, Williams and Wilkins, Baltimore, 1996. pp. 575-600.
4. Bingaman K, Olson JJ: Cranial Bone Flap Infections and Osteomyelitis of the Skull, in Osenback RK, and Zeidman SM (eds): *Infections of the Central Nervous System: Diagnosis and Management*. Lippincott-Raven, Philadelphia, 1999. pp. 65-84.
5. Olson, JJ, Barrow D, Gilbert M, Oyesiku N: Intracranial Tumors in Morris PJ, Wood WC (eds) *Oxford Textbook of Surgery*. Oxford University Press, New York, 2000. pp. 2801-2828.
6. Shinazi RF, Hurwitz S, Liberman I, Juodawlkis A, Shi J, Liotta DC, Coderre J, Olson J: Preclinical Development of b-D-5-o carboranyl-2'-deoxyuridine (D-CDU) for the Treatment of Malignant Brain Tumors in Hawthorne F, et al (eds): *Frontiers in Neutron Capture Therapy*. Kluwer Academic/Plenum Publishers, New York, 2001. pp. 1121-1124.
7. Olson JJ, Bowers G, Zhang Z: Proteasome inhibitors in a brain tumor model, in Adams J (ed) *Cancer Drug Discovery and Development: Proteasome Inhibitors in Cancer Therapy*. Humana Press, Inc., Totowa, NJ, 2004. Pp. 161-70.
8. Ormond DR, Bouras A, Moore M, Gary M, Province P, Prabhu R, Egan KM, Rangaraju S, Appin, C, Hadjipanayis C, Nabors B, Voloschin A, Olson JJ: Central Nervous System and Peripheral Nerve Tumors in Gansler T (ed) *American Cancer Society Textbook of Cancer*, Accepted February 20, 2014, *In Press*.

Book Reviews

1. The Role of Surgery in Brain Tumor Management, Rosenblum ML (ed.) *Neurosurgery* 28:331-2, 1991.
2. Cerebral radiation necrosis, Olson JJ. *Perspectives in Neurological Surgery*, Barrow DL (ed.), Quality Medical Publishing, St. Louis, pp. 141-142, 1991.
3. Radiation Injury to the Nervous System, Gutin PH, Leibel SA , Sheline GE (eds.) *Neurosurgery*.
4. *Surgery for Skull Base Tumors*, Donlin Long (ed.) *J Neurosurgery*. 1993.
5. *Astrocytomas: Diagnosis, Treatment and Biology*, Black PM, Schoene WC, Lampson LA, (eds.) *Neurosurgery*, 1994.
6. *Handbook of Stereotaxy for the CRW Apparatus*. Pell MF, Thomas DGT (eds). *J Neurosurgery*, 1994.

7. Benign Cerebral Glioma, Volume I and II. Apuzzo MLJ (ed). J Neurosurg, February, 1996.
8. Gene Therapy for Neurological Disorders and Brain Tumors. Chiocca A, Breakefield XO (eds). J Neurosurgery, December, 1998.
9. Considerations in the Diagnosis and Management of Brain Metastases. Raymond Sawaya. Oncology 15: 1164-1165, 2001

Texts

1. Skull Base Surgery: Basic Techniques. Moore CE, Olson JJ (eds.), Plural Publishing, San Diego, CA, 2010.

Review Articles

1. Olson JJ: Recurrent gliomas. Neurosurgical Consultations Vol. 3(18), 1992.
2. James CD, Olson JJ: Molecular genetics and molecular biology advances in brain tumors. Current Opinion in Oncology 8: 188-195, 1996.
3. Suh DY, Olson JJ: Management of recurrent malignant primary brain tumors. Part I: Etiology, clinical diagnosis, and treatment options. Contemporary Neurosurgery 20 (11), June, 1998.
4. Suh DY, Olson JJ: Management of recurrent malignant primary brain tumors. Part II: Chemotherapy, radiation and radiosurgery, brachytherapy, and decision making. Contemporary Neurosurgery 20 (12), June, 1998.
5. Olson JJ: Neurosurgical Advances in the Treatment of Brain Tumors. Current Oncology Reports 2: 434-437, 2000.
6. Narayan P, Olson JJ: Management of Anaplastic Astrocytomas. Contemporary Neurosurgery 23 (24), 2001.

Book Chapters

1. Morgan JS, Olson JJ: Steroid hormones and meningiomas. Meningiomas and Their Surgical Management, H.H. Schmidek (ed.), W.B. Saunders, Philadelphia, pp. 48-55. 1991.
2. Olson JJ, Reisner A: Craniotomy for Brain Tumor in M.F. Lubin, K. Walker, R.B. Smith, III (eds), Medical Management of the Surgical Patient, 3rd Ed. J.B. Lippincott, Philadelphia, 1994.
3. Olson JJ, Rossi J: Radiobiology of the Central Nervous System. Tindall GT, Cooper P, Barrow D (eds) Practice of Neurosurgery, Williams and Wilkins, Baltimore, 1996. pp. 575-600.

4. Bingaman K, Olson JJ: Cranial Bone Flap Infections and Osteomyelitis of the Skull, in Osenback RK, and Zeidman SM (eds): Infections of the Central Nervous System: Diagnosis and Management. Lippincott-Raven, Philadelphia, 1999. pp. 65-84.
5. Olson, JJ, Barrow D, Gilbert M, Oyesiku N: Intracranial Tumors in Morris PJ, Wood WC (eds) Oxford Textbook of Surgery. Oxford University Press, New York, 2000. pp. 2801-2828.
6. Shinazi RF, Hurwitz S, Liberman I, Juodawlkis A, Shi J, Liotta DC, Coderre J, Olson J: Preclinical Development of b-D-5-o carboranyl-2'-deoxyuridine (D-CDU) for the Treatment of Malignant Brain Tumors in Hawthorne F, et al (eds): Frontiers in Neutron Capture Therapy. Kluwer Academic/Plenum Publishers, New York, 2001. pp. 1121-1124.
7. Olson JJ, Bowers G, Zhang Z: Proteasome inhibitors in a brain tumor model, in Adams J (ed) Cancer Drug Discovery and Development: Proteasome Inhibitors in Cancer Therapy. Humana Press, Inc., Totowa, NJ, 2004. Pp. 161-70.

Book Reviews

1. The Role of Surgery in Brain Tumor Management, Rosenblum ML (ed.) Neurosurgery 28:331-2, 1991.
2. Cerebral radiation necrosis, Olson JJ. Perspectives in Neurological Surgery, Barrow DL (ed.), Quality Medical Publishing, St. Louis, pp. 141-142, 1991.
3. Radiation Injury to the Nervous System, Gutin PH, Leibel SA , Sheline GE (eds.) Neurosurgery.
4. Surgery for Skull Base Tumors, Donlin Long (ed.) J Neurosurgery. 1993.
5. Astrocytomas: Diagnosis, Treatment and Biology, Black PM, Schoene WC, Lampson LA, (eds.) Neurosurgery, 1994.
6. Handbook of Stereotaxy for the CRW Apparatus. Pell MF, Thomas DGT (eds). J Neurosurgery, 1994.
7. Benign Cerebral Glioma, Volume I and II. Apuzzo MLJ (ed). J Neurosurg, February, 1996.
8. Gene Therapy for Neurological Disorders and Brain Tumors. Chiocca A, Breakefield XO (eds). J Neurosurgery, December, 1998.
9. Considerations in the Diagnosis and Management of Brain Metastases. Raymond Sawaya. Oncology 15: 1164-1165, 2001

